ClinicalTrials.gg
CompletedNCT00478205Updated Jul 11, 2014Results posted

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

A Phase 3 interventional study of Aricept (donepezil SR 23 mg) and Aricept (donepezil IR 10 mg) in Alzheimer's Disease, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 45 Years to 90 Years. Per ClinicalTrials.gov, last updated 2014-07-11.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,467
Allocation
Randomized
Ages
45 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
Largest of 58
1,467 · median 79
Started
2007
with 4 others
Phase 3
10 of 60
1 open now
Registered
15th of 60
by date
Lead sponsor
9 of 60
Eisai Inc.

Among the 60 studies testing donepezil in Alzheimer Disease, this one has the largest enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2007, is one of 10 in phase 3, and was the 15th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 45 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease.

Read the detailed description

This study consists of a double-blind, double-dummy, parallel-group comparison of 23 mg donepezil SR with the currently marketed donepezil formulation (10 mg donepezil IR) in patients with moderate to severe Alzheimer's disease. Patients must have been taking 10 mg IR (or a bioequivalent generic) for at least 3 months prior to Screening. The study will consist of 24 weeks of daily administration of study medication, with clinic visits at Screening, Baseline, 3 weeks (safety only), 6 weeks, 12 weeks, 18 weeks and 24 weeks or early termination. Patients will receive either 10 mg donepezil IR in combination with the placebo corresponding to 23 mg donepezil SR, or 23 mg donepezil SR in combination with the placebo corresponding to 10 mg donepezil IR.

A total of approximately 1600 patients will be enrolled to obtain complete data from approximately 1200 completed patients (Revised per Amendment 02). During the Baseline visit, patients will be randomized in a 2:1 ratio (23 mg donepezil SR to 10 mg donepezil IR). The study will be performed at approximately 200 global sites (Asia, Oceania, Europe, India, Israel, North America, South Africa, and South America) (Revised per Amendments 01 and 02). An Independent Data Monitoring Committee (IDMC) will be established to review safety aspects of the study and to evaluate the results of a planned interim analysis.

Patients who complete the study may be eligible to undergo evaluation for enrollment into the open-label extension study, E2020-G000-328.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Moderate to Severe Alzheimer's Disease
04

Who can participate

Ages eligible
45 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Patients:

  1. Written .
  2. Patient Age range: Adult patients, 45 to 90 years of age, inclusive.
  3. The caregiver must separately meet the specified inclusion/exclusion criteria for caregivers.
  4. Women must be of non- (>1 year or surgically sterile).
  5. There must be diagnostic evidence of probable Alzheimer's disease (AD).
  6. The patient must have been receiving Aricept at a dose of dose of 10 mg IR (or 10 mg dose of generic donepezil bioequivalent to Aricept), for at least 3 months prior to the Screening visit.
  7. A cranial image is required, with no evidence of focal brain disease that would account for dementia.
  8. The patient must meet certain psychometric test criteria related to the degree of impairment of cognitive functioning.
  9. Health: physically healthy and ambulatory or ambulatory-aided (i.e., walker or cane); corrected vision and hearing sufficient for compliance with testing procedures, and able to read prior to disease onset.
  10. Clinical laboratory values must be within normal limits or, if abnormal, must be judged not by the investigator.
  11. Specified doses of selective serotonin reuptake inhibitors (SSRIs) are allowed in the study if dosage is within approved dose range and stable for 3 months prior to Screening.
  12. Other medical conditions, such as hypertension and cardiac disease must be well-controlled and the patient maintained on stable doses of medications for 3 months.
  13. Patients with diabetes mellitus or risk factors for diabetes mellitus may be enrolled in the study provided that the patient's disease is stable and that there have been no recent hospitalizations for diabetes complications.
  14. Patients whose serum B12 levels at Screening are below the normal range may nonetheless be admitted to the study if they subsequently show normal levels prior to Baseline.
  15. Patients with hypothyroidism who are on a stable dose of medication for at least 12 weeks prior to Screening, have normal TSH and free T4 at Screening, and are considered euthyroid will be eligible.
  16. Concomitant Medications: Under specified circumstances, the following medications may be allowed: chronic daily benzodiazepine use, bronchodilator medications for treatment of (COPD), and memantine. Certain other additional prescription treatments for AD, such as other cholinesterase inhibitors, must have been discontinued for at least 3 months prior to screening.
  17. The patient must have a relative/caregiver who supervises the regular taking of the drug at the correct dose and is alert for possible side effects, unless the patient's legal guardian takes on this task.

Inclusion Criteria for Caregivers:

The designated caregiver must be sufficiently familiar with the patient (as determined by the investigator) to provide accurate data. The caregiver must have regular contact with the patient (i.e., an average of 10 or more hours per week), must be able to observe for possible adverse events, and must be able to accompany the patient to all visits.

Exclusion Criteria for Patients:

  1. Patients are excluded if they are taking (a) no medication for Alzheimer's disease, (b) Aricept or bioequivalent generic donepezil at doses other than 10 mg daily, or 10 mg for less than 3 months before Screening; (c) other medications for Alzheimer's disease, except that memantine, Vitamin E, fish oil, and/or gingko biloba are allowed if doses have been stable for at least 3 months prior to the Screening visit. Patients undergoing any alternative medical techniques, such as acupuncture or acupressure, specifically for the treatment of AD are not eligible
  2. No caregiver available to meet the inclusion criteria for caregivers.
  3. Patients who have no measurable blood levels of donepezil in blood samples collected at Screening.
  4. Patients with neurological disorders that affect cognition or the ability to assess cognition but are distinguishable from Alzheimer's disease. These include, but are not limited to, Parkinson's disease, multi-infarct dementia, and dementia due to cerebrovascular disease.
  5. Patients with psychiatric disorders affecting the ability to assess cognition such as schizophrenia, bipolar or unipolar depression. Patients with clinically significant sleep disorders will also be excluded unless these are controlled by treatment and clinically stable for > 3 months prior to screening.
  6. Patients with dementia complicated by other organic disease or Alzheimer's disease with delirium.
  7. Patients with drug or alcohol abuse or dependence within the past 5 years according to DSM IV criteria.
  8. Patients with any conditions affecting absorption, distribution, or metabolism of the study medication (e.g., inflammatory bowel disease, gastric or duodenal ulcers, hepatic disease, or severe lactose intolerance).
  9. Patients with evidence of clinically significant, active gastrointestinal, renal, hepatic, respiratory, endocrine, or cardiovascular system disease (including history of life-threatening arrhythmias).
  10. Patients with a history of cancer (does not include basal or squamous cell carcinoma of the skin) treated within 5 years prior to study entry, or current evidence of malignant neoplasm, recurrent, disease. Males with localized prostate cancer requiring no treatment would not be excluded.
  11. Known plan for elective surgery during the treatment period that would require general anesthesia and administration of neuromuscular blocking agents.
  12. Donation of blood or blood products during 30 days prior to Screening or plans to donate blood while participating in the study or within 30 days after completion of the study.
  13. Patients who are unwilling or unable to fulfill the requirements of the study.
  14. Known to acetylcholinesterase inhibitors or memantine.
  15. Use of any prohibited prior or concomitant medications) Any condition that would make the patient, in the opinion of the investigator, unsuitable for the study.
  16. Involvement in any other drug clinical trial during the preceding 3 months, or likely involvement in any other such trial during the course of this study.
  17. Patients taking concomitant antidepressant medication known to have significant anticholinergic effects, such as tricyclic antidepressants prescribed at doses recommended for the treatment of major depression.
  18. Patients who cannot swallow or who have difficult swallowing whole tablets.
  19. Patients with fecal and/or urinary incontinence who are unable to cooperate with routine specimen collection.

Exclusion Criteria for Caregivers:

  1. Caregivers who are unwilling or unable to give informed consent or otherwise to fulfill the requirements of the study.
  2. Caregivers who do not meet certain psychometric test criteria.
  3. Any condition that would make the caregiver, in the opinion of the Investigator, unsuitable for the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,467 participants (actual)

Study arms

  • Experimental
    1

    Drug: Aricept (donepezil SR 23 mg)

  • Experimental
    2

    Drug: Aricept (donepezil IR 10 mg)

Interventions

  • Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design: 23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation.

    Also known as: Donepezil hydrochloride

  • Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design: 10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation.

    Also known as: Donepezil hydrochloride

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 24 in SIB Total Score

    The SIB is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best). This outcome was calculated using the LOCF (last observation carried forward) method.

    Time frame: Baseline and Week 24

  2. Overall Change From Baseline in Modified CIBIC+ to Week 24

    The CIBIC+ is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening).

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline to Week 24 in ADCS-ADL Total Score

    The ADCS-ADL (Alzhemier's Disease Cooperative Study-Activities of Daily Living) is a 19-item assessment scale used to measure a patient's basic functional abilities, such as walking, grooming, and bathing.Scores range from 0 to 54, with a higher score indicating greater functional ability.

    Time frame: Baseline and Week 24

  2. Change From Baseline to Week 24 in MMSE Total Score

    The MMSE (Mini-Mental State Examination) is a 30-item test that evaluates 5 domains of cognitive function (orientation to time and place, immediate and delayed recall, attention, calculation, and language). The scores range from 0 (most impaired) to 30 (no impaiment).

    Time frame: Baseline and Week 24

07

Results

Posted Feb 5, 2013

Participant flow

Participant flow — Overall Study
MilestoneDonepezil SR 23 mgDonepezil IR 10 mg
Started981486
Completed685399
Not completed29687
Withdrew: Adverse event18239
Withdrew: Medication non-compliance94
Withdrew: Protocol violation155
Withdrew: Request of investigator or sponsor45
Withdrew: Withdrawal by subject6122
Withdrew: Lack of efficacy10
Withdrew: Other2412

Outcome measures

PrimaryChange From Baseline to Week 24 in SIB Total Score

The SIB is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best). This outcome was calculated using the LOCF (last observation carried forward) method.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline to Week 24 in SIB Total Score
Scores on a scaleDonepezil SR 23 mgDonepezil IR 10 mg
Change From Baseline to Week 24 in SIB Total Score2.6 ± 0.580.4 ± 0.66
SecondaryChange From Baseline to Week 24 in ADCS-ADL Total Score

The ADCS-ADL (Alzhemier's Disease Cooperative Study-Activities of Daily Living) is a 19-item assessment scale used to measure a patient's basic functional abilities, such as walking, grooming, and bathing.Scores range from 0 to 54, with a higher score indicating greater functional ability.

Time frame:
Baseline and Week 24
Reported as:
Mean · Scores on a scale
Change From Baseline to Week 24 in ADCS-ADL Total Score
Scores on a scaleDonepezil SR 23 mgDonepezil IR 10 mg
Change From Baseline to Week 24 in ADCS-ADL Total Score-1.2 ± 6.83-1.2 ± 6.78
SecondaryChange From Baseline to Week 24 in MMSE Total Score

The MMSE (Mini-Mental State Examination) is a 30-item test that evaluates 5 domains of cognitive function (orientation to time and place, immediate and delayed recall, attention, calculation, and language). The scores range from 0 (most impaired) to 30 (no impaiment).

Time frame:
Baseline and Week 24
Reported as:
Mean · Scores on a scale
Change From Baseline to Week 24 in MMSE Total Score
Scores on a scaleDonepezil SR 23 mgDonepezil IR 10 mg
Change From Baseline to Week 24 in MMSE Total Score0.6 ± 2.930.4 ± 3.20
PrimaryOverall Change From Baseline in Modified CIBIC+ to Week 24

The CIBIC+ is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening).

Time frame:
Baseline and Week 24
Reported as:
Mean · Scores on a scale
Overall Change From Baseline in Modified CIBIC+ to Week 24
Scores on a scaleDonepezil SR 23 mgDonepezil IR 10 mg
Overall Change From Baseline in Modified CIBIC+ to Week 244.23 ± 1.074.29 ± 1.07

Adverse events

Collected over All adverse events (AEs) were recorded from the time of informed consent until after the Final Visit or Early Termination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donepezil SR 23 mg—80/963 (8.3%)233/963 (24.2%)
Donepezil IR 10 mg—45/471 (9.6%)50/471 (10.6%)
Most frequent serious events
Showing 10 of 126
Most frequent serious events
EventDonepezil SR 23 mgDonepezil IR 10 mg
SyncopeNervous system disorders2/9635/471
AggressionPsychiatric disorders2/9634/471
PneumoniaInfections and infestations3/9633/471
Confusional statePsychiatric disorders1/9633/471
Urinary tract infectionInfections and infestations6/9632/471
FallInjury, poisoning and procedural complications6/9632/471
HypothermiaGeneral disorders1/9632/471
ConvulsionNervous system disorders0/9632/471
Atrial fibrillationCardiac disorders4/9631/471
BradycardiaCardiac disorders4/9630/471
Most frequent other events
Most frequent other events
EventDonepezil SR 23 mgDonepezil IR 10 mg
NauseaGastrointestinal disorders113/96316/471
VomitingGastrointestinal disorders86/96312/471
DiarrhoeaGastrointestinal disorders76/96325/471
AnorexiaMetabolism and nutrition disorders51/9638/471

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Donepezil SR 23 mgDonepezil IR 10 mgTotal
Mean73.9 ± 8.5373.8 ± 8.5673.8 ± 8.53
Sex: Female, Male
Sex: Female, Male(Participants)Donepezil SR 23 mgDonepezil IR 10 mgTotal
Female607 ± 63.0294 ± 62.4901 ± 62.8
Male356 ± 37.0177 ± 37.6533 ± 37.2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Donepezil SR 23 mgDonepezil IR 10 mgTotal
Black22931
White7083461054
Hispanic672693
Native American000
Asian/Pacific16187248
Other538
08

Study locations

1 site
  • MedTrials, Inc.
    Hickory, North Carolina 28601, United States
09

References and documents

Publications

  • Schmitt FA, Saxton J, Ferris SH, Mackell J, Sun Y. Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study. Int J Clin Pract. 2013 Oct;67(10):1050-6. doi: 10.1111/ijcp.12188. PubMed 24073978 ↗
  • Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, Mackell J. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2012 Sep;27(6):421-32. doi: 10.1177/1533317512454708. PubMed 22930699 ↗
  • Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012;33(2-3):164-73. doi: 10.1159/000338236. Epub 2012 May 10. PubMed 22572767 ↗
  • Ferris SH, Schmitt FA, Saxton J, Richardson S, Mackell J, Sun Y, Xu Y. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimers Res Ther. 2011 Jun 20;3(3):22. doi: 10.1186/alzrt84. PubMed 21689411 ↗
  • Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, Zou H, Hsu T, Satlin A. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurol. 2011 May 25;11:57. doi: 10.1186/1471-2377-11-57. PubMed 21612646 ↗
  • Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther. 2010 Jul;32(7):1234-51. doi: 10.1016/j.clinthera.2010.06.019. PubMed 20678673 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007 and a primary completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 3 years 8 months after primary completion. A results delay was requested in Feb 2010.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2007
First posted
May 24, 2007
Start
Jun 2007
Primary completionActual
Jun 2009
Results delay requested
Feb 17, 2010
Results first posted
Feb 5, 2013
Last update
Jul 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00478205
Lead sponsor
Eisai Inc.
Collaborators
Eisai Limited
Responsible party
Sponsor
First posted
May 24, 2007
Start date
Jun 2007
Primary completion
Jun 2009
Results posted
Feb 5, 2013
Last update
Jul 11, 2014

Study contacts

Jane Yardley, Ph.D
study director · Eisai Limted
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion